Canon buys $40m stake in T2 Biosystems

Canon U.S.A. (NYSE:CAJ) said today it made a $40 million dollar equity investment into diagnostic developer T2 Biosystems Inc. (NSDQ:TTOO), giving Canon a 19.9% stake. Canon said it purchased approximately $40 million of T2’s stock at $6.56 per share through a private placement. The investment isn’t the 1st pairing for Canon and T2, as both companies have been collaborating to develop a diagnostic test panel for rapidly detecting Lyme disease since February 2015. “We recognize that both T2 Biosystems and Canon U.S.A. are aligned in working towards the same goal and as such, we are pleased to strengthen our relationship and look forward to bringing future innovative diagnostic products to market that can improve patient health. Investments to companies like T2 is another example of Canon’s commitment in healthcare,” Canon U.S.A. CEO &chair Joe Adachi said in a press release. Canon U.S.A. exec veep, chief administrative officer and GC Seymore Liebman will join T2 Biosystems’ board of directors as part of the deal, the companies said. “The strong backing and commitment we have received from Canon will help us continue to strengthen our business and accelerate our efforts to bring new products to market. We look forward to continuing our partnership with Canon,” T2 Biosystems CEO John McDonough said in prepared remarks. Shares in T2 Biosystems have jumped up 12.2% in mid day trading, at $7.29 a...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Diagnostics Canon T2 Biosystems Inc. Source Type: news

Related Links:

Conditions:   Joint Infection;   Infection of Hip Joint (Disorder);   Infection of Shoulder Joint;   Septic Arthritis Interventions:   Diagnostic Test: Synovial Alpha-defensin assay;   Diagnostic Test: Synovial Neutrophil elastase assay;   Diagnostic Test: Synovial lactate assay;   Diagnostic Test: Synovial C-reactive Protein (CRP);   Diagnostic Test: Synovial Staphylococcus spp antigen panel;   Diagnostic Test: Sy novial Candida spp antigen panel;   Diagnostic Test: Synovial Enterococ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(Rutgers University) Researchers have developed techniques to detect Lyme disease bacteria weeks sooner than current tests, allowing patients to start treatment earlier.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
t Ngan Young Hoon The range of Ixodes scapularis is expanding in Ontario, increasing the risk of Lyme disease. As an effective public health response requires accurate information on disease distribution and areas of risk, this study aims to establish the geographic distribution of I. scapularis and its associated pathogen, B. burgdorferi, in northwestern Ontario. We assessed five years of active and passive tick surveillance data in northwestern Ontario. Between 2013 and 2017, 251 I. scapularis were submitted through passive surveillance. The submission rate increased over time, and the proportion infected with B. bur...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
Molecular Microbiology,Volume 0, Issue ja, -Not available-.
Source: Molecular Microbiology - Category: Microbiology Authors: Source Type: research
-- People aren't the only ones who are vulnerable to Lyme disease. Fido or Fluffy also could contract the illness from an infected tick. The American Kennel Club says Lyme disease occurs the most often in the Northeast, the Upper Midwest and on the...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
(MedPage Today) -- Meta-analysis finds little difference in efficacy, adverse effects
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news
Publication date: Available online 26 September 2018Source: Ticks and Tick-borne DiseasesAuthor(s): R. Dersch, A. Sarnes, M. Maul, O. Minakowski, T. Hottenrott, O. Stich, S. RauerAbstractAbout 5–20% of the general population in endemic areas have seroprevalence for anti-borrelial antibodies. Previous studies have shown a high rate of 25–97% of persisting anti-borrelial antibodies in patients with treated Lyme neuroborreliosis (LNB) at follow-up. These studies used immunoblots with antigens from whole-cell sonicates, which could be less specific than modern recombinant antigens. We assessed the seroprevalence of...
Source: Ticks and Tick borne Diseases - Category: Zoology Source Type: research
PMID: 30277741 [PubMed - in process]
Source: American Family Physician - Category: Primary Care Authors: Tags: Am Fam Physician Source Type: research
This network meta-analyses of 19 randomized clinical trials conducted in the United States and Europe examines antibiotic agents and treatment modalities to assess treatment effectiveness and drug-related adverse outcomes in early cutaneous Lyme borreliosis.
Source: JAMA Dermatology - Category: Dermatology Source Type: research
Abstract Lyme disease (borreliosis) is a tick-borne bacterial infection caused by the spirochaete Borrelia burgdoferi, transmitted by hard-backed Ixodes ticks. Actual numbers of cases are increasing and it appears that the distribution across the UK is widening; however, it occurs most frequently in area of woodland, with temperate climate. It typically presents in mid to late summer. Lyme disease is a multisystem disease. The nervous system is the second most commonly affected system after the skin. Other systemic manifestations, such as carditis, keratitis, uveitis and inflammatory arthritis, rarely occur in Eur...
Source: Practical Neurology - Category: Neurology Authors: Tags: Pract Neurol Source Type: research
More News: Health | Lyme Disease | Partnerships